Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

L. Letendre; P. Noel; A. Tefferi; L. A. Solberg; D. A. Gastineau; H. C. Hoagland

doi:10.1097/00000421-199510000-00003

Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

L. Letendre, P. Noel, A. Tefferi, L. A. Solberg, D. A. Gastineau, H. C. Hoagland

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Etoposide (125 mg/m²/d) and carboplatin (200 mg/m²/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.

Original language	English (US)
Pages (from-to)	382-384
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	18
Issue number	5
DOIs	https://doi.org/10.1097/00000421-199510000-00003
State	Published - 1995

Keywords

Enterocolitis
Etoposide/carboplatin
Leukemia

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-199510000-00003

Cite this

@article{08628e3b55214d5d959bf12d8761e759,

title = "Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia",

abstract = "Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.",

keywords = "Enterocolitis, Etoposide/carboplatin, Leukemia",

author = "L. Letendre and P. Noel and A. Tefferi and Solberg, {L. A.} and Gastineau, {D. A.} and Hoagland, {H. C.}",

year = "1995",

doi = "10.1097/00000421-199510000-00003",

language = "English (US)",

volume = "18",

pages = "382--384",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

AU - Letendre, L.

AU - Noel, P.

AU - Tefferi, A.

AU - Solberg, L. A.

AU - Gastineau, D. A.

AU - Hoagland, H. C.

PY - 1995

Y1 - 1995

N2 - Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.

AB - Etoposide (125 mg/m2/d) and carboplatin (200 mg/m2/d) were administered by continuous 5-day intravenous infusion to 10 patients with relapsed or refractory acute leukemia (7 ANLL, 1 ALL, 2 blast crisis of CGL). No complete or partial response was observed despite dose-limiting toxicity characterized by severe diarrhea in four patients and neutropenic colitis in two additional cases. We cannot recommend the present schedule of drug administration for the treatment of acute leukemia.

KW - Enterocolitis

KW - Etoposide/carboplatin

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0029087537&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029087537&partnerID=8YFLogxK

U2 - 10.1097/00000421-199510000-00003

DO - 10.1097/00000421-199510000-00003

M3 - Article

C2 - 7572751

AN - SCOPUS:0029087537

SN - 0277-3732

VL - 18

SP - 382

EP - 384

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 5

ER -

Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this